Adult Relapsed Refractory B-cell Acute Lymphoblastic Leukemia: 2021 Updates

home / insights / adult-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-2021-updates

Recommendations for assessing and treating patients with relapsed/refractory B-cell ALL based on more recent data presented at ASH 2021.

EP. 1: Relapsed Refractory B-Cell ALL: Patient Prognosis

Elias Jabbour, MD;Jae Park, MD

January 25th 2022

Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.

EP. 2: Relapsed Refractory B-Cell ALL: Treatment Overview

Elias Jabbour, MD

January 25th 2022

The treatment approaches available for patients with B-cell acute lymphoblastic leukemia, and reactions to the availability of novel CAR T therapies for relapsed/refractory disease.

EP. 3: CAR T Therapy for Relapsed/Refractory B-Cell ALL: Selecting Appropriate Patients

Elias Jabbour, MD;Jae Park, MD

February 1st 2022

Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

EP. 4: CAR-T Therapy for Relapsed/Refractory B-Cell ALL: Sequencing Decisions

Elias Jabbour, MD;Jae Park, MD

February 1st 2022

Recommendations for sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.

EP. 5: Relapsed/Refractory B-Cell ALL: CAR-T Safety Profiles

Elias Jabbour, MD;Jae Park, MD

February 8th 2022

An overview of adverse events commonly associated with CAR T-cell therapies in relapsed/refractory B-cell acute lymphoblastic leukemia.

EP. 6: Emerging Novel Therapies for Relapsed/Refractory B-Cell ALL

Elias Jabbour, MD

February 8th 2022

Emerging therapies in the clinical pipeline for relapsed/refractory B-cell acute lymphoblastic leukemia, as presented at ASH 2021.

EP. 7: MRD Assessments in B-Cell ALL

Elias Jabbour, MD;Jae Park, MD

February 15th 2022

When to test for measurable residual disease in B-cell acute lymphoblastic leukemia, and what to keep in mind when selecting a testing method to help assess MRD.

EP. 8: Relapsed/Refractory B-Cell ALL: Adopting MRD Testing into Routine Practice

Elias Jabbour, MD;Jae Park, MD

February 15th 2022

The significance of having novel therapies and molecular tests available to help guide treatment decisions for patients with B-cell acute lymphoblastic leukemia, and recommendations on how to increase the uptake of MRD testing into routine clinical practice.

EP. 9: R/R B-Cell ALL: Is There a Role for Transplantation?

Elias Jabbour, MD;Jae Park, MD

February 22nd 2022

Discussion on the role of transplantation in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

EP. 10: B-Cell ALL: Integrating Novel Therapies Into Real-World Practice

Elias Jabbour, MD;Jae Park, MD

February 22nd 2022

Expectations regarding where novel therapies such as CAR T-cell therapies will fit into B-cell acute lymphoblastic leukemia treatment algorithms as data from clinical trials continue to evolve.